Patients with lung cancer CEA carbohydrate antigen levels and staging of lung cancer metastasis and prognosis of.doc

 PAGE \* MERGEFORMAT 11 Patients with lung cancer CEA carbohydrate antigen levels and staging of lung cancer metastasis and prognosis of [Abstract] Objective: To investigate the peripheral blood of cancer patients with lung cancer antigen (CEA), carbohydrate antigen (CA19-9, CA125, CA15-3) levels and tumor stage, metastasis and prognosis. Methods: The IMMULITE chemiluminescent immunoassay enzyme amplification assay of lung cancer, benign lung diseases and healthy controls were 30 patients in each peripheral blood CEA, CA19-9, CA125, CA15-3 levels. Patients were followed up for 2 years. Results: The patients with lung cancer CEA, CA125, CA15-3 levels higher than those of benign lung disease patients and healthy controls, the difference was significant (P amp;lt;0.05 or P amp;lt;0.01); lung cancer patients with CA19-9 levels and healthy controls There were significant difference (P amp;lt;0.05), benign lung disease patients with no significant difference. Among cancer patients at different stages of serum CEA, carbohydrate antigen was no significant difference in the level. CEA and CA125-positive patients with lung cancer metastasis and recurrence was significantly higher than the chances of negative patients, their difference was significant (P amp;lt;0.01), the follow-up period a total of 14 patients died of lung cancer recurrence or metastasis. The prognosis of patients with positive serum CEA significantly worse than negative patients, the difference between the survival rate was significantly (P amp;lt;0.05). Conclusion: The peripheral blood CEA, carbohydrate antigen (CA125) levels of dynamic detection of lung cancer metastasis and prognosis of certain clinical significance. [Keywords:] lung cancer antigen carbohydrate antigen Abstract: Objective: To study the value of serum carcinoembryonic antigen (CEA) and carbohydrate antigens (CA15-3, CA19-9 and CA125) in staging, metastasis and prognosis of patients with lung cancer. Methods: The level of CEA, CA15